Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/ *1 carriers

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 617-627

  Mlynarsky, Liat ^a   Bejarano Achache, Idit ^a   Muszkat, Mordechai ^a   Caraco, Yoseph ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Anticoagulation; Factor VII; Genetic polymorphism; Warfarin

Indexed keywords

AMIODARONE; AMOXICILLIN; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ARGININE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 7; CEFUROXIME; DIGOXIN; GLUTAMINE; ROXITHROMYCIN; SULTAMICILLIN; WARFARIN;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CYP2C9 GENE; DEEP VEIN THROMBOSIS; DRUG RESPONSE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; VKORC1 GENE;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ATRIAL FIBRILLATION; COHORT STUDIES; DRUG MONITORING; DRUG RESISTANCE; FACTOR VII; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; ISRAEL; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; VENOUS THROMBOSIS; WARFARIN; YOUNG ADULT;

EID: 84864279402     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1143-z     Document Type: Article

References (36)

1. Lamb E (2007) Top 200 prescription drugs of 2006. Pharm Times May:34-37
2. Wallvik J, Själander A, Johansson L, Bjuhr O, Jansson JH (2007) Bleeding complications during warfarin treatment in primary healthcare centers compared with anticoagulation clinics. Scand J Prim Health Care 25(2):123-128 (Pubitemid 46752224)
3. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115(21):2689-2696 (Pubitemid 46842784)
4. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH (1996) The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 124(11):970-979
5. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423-429
6. Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H et al (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95:205-211
7. Stafford DW (2005) The vitamin K cycle. J Thromb Haemost 3:1873-1878 (Pubitemid 41716574)
8. Caraco Y, Blotnick S, Muszkat M (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83:460-470 (Pubitemid 351272635)
9. Millican EA, Lenzini PA, Milligan PE, Grosso L, Eby C, Deych E et al (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110(5):1511-1515 (Pubitemid 47443966)
10. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16(2):101-110 (Pubitemid 43145678)
11. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A et al (2001) Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther 70:159-164
12. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72(6):702-710 (Pubitemid 36021009)
13. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and Warfarin dose. N Engl J Med 352:2285-2293 (Pubitemid 40740552)
14. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S et al (2009) The largest prospective warfarintreated cohort supports genetic forecasting. Blood 113(4):784-792
15. The International Warfarin Pharmacogenetics Consortium (2009) Estimation of the Warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-764
16. Bertolaa JP, Mazoyerb E, Bergmanna JFO, Drouetb L, Simoneaua G, Mahe I (2003) Early prediction of the sensitivity of warfarin in elderly patients by the fall in factor VIIc and protein C at the induction of treatment. Thromb Res 109:287-291 (Pubitemid 36724823)
17. Green FR, Kelleher C, Wilkes H, Temple A, Meade TW, Humphries SE (1991) A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. Arterioscler Thromb 11:540-546
18. Van't Hooft FM, Silveira A, Tornvall P, Iliadou A, Ehrenborg E, Eriksson P et al (1999) Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. Blood 93:3432-3441 (Pubitemid 29220910)
19. Grimaudo S, Craxi A, Gentile S, Di Paolantonio T, Vaccaro A, Venezia G et al (2005) Prolonged prothrombin time, Factor VII and activated FVII levels in chronic liver disease are partly dependent on Factor VII gene polymorphisms. Dig Liver Dis 37 (6):446-450 (Pubitemid 44356047)
20. Mtiraoui N, Aboud N, Bouraoui H, Haizem S, Gris JC, Busson M et al (2005) Reduction in coagulation factor VII plasma levels by R353Q but not the - 323P0/10 promoter polymorphism in healthy Tunisians. Am J Hematol 79:11-16 (Pubitemid 40604786)
21. Jeffery S, Poloniecki J, Leatham E, Bevan D, Ireson N, Talbot S et al (2005) A protective contribution of the Q allele of the R353Q polymorphism of the Factor VII gene in individuals with chronic stable angina? Int J Cardiol 100:395-399
22. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D et al (2006) Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79(4):291-302
23. Lane A, Green F, Humphries S, Ruddock V, Meade T (1995) Effect of factor VII genotype on response to warfarin treatment. Thromb Haemost 73(2):325
24. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T et al (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630-2635 (Pubitemid 38393017)
25. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C et al (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23-34 (Pubitemid 46421137)
26. Ken-Dror G, Drenos F, Humphries SE, Talmud PJ, Hingorani AD, Kivimaki et al (2010) Haplotype and genotype effects of the F7 gene on circulating factor VII, coagulation activation markers and incident coronary heart disease in UK men. J Thromb Haemost 8:2394-2403
27. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5(3):e1000433, Epub 2009 Mar 20
28. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):160S-198S (Pubitemid 351892967)
29. Dell'Acqua G, Iacoviello L, D'Orazio A, Di Bitondo R, Di Castelnuovo A, Donati MB (1997) A polymorphic cluster in the 5' region of the human coagulation factor VII gene: detection, frequency, and linkage disequilibrium. Thromb Res 88(5):445-448 (Pubitemid 28186735)
30. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254(3):628-631 (Pubitemid 29290517)
31. Gaunt TR, Rodríguez S, Day IN (2007) Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'. BMC Bioinformatics 8:428
32. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS (2005) Systematic overview of Warfarin and its drug and food interactions. Arch Intern Med 165:1095-1106 (Pubitemid 40720733)
33. Feng D, Tofler GH, Larson MG, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA et al (2000) Factor VII gene polymorphism, Factor VII levels, and prevalent cardiovascular disease: the Framingham heart study. Arterioscler Thromb Vasc Biol 20:593-600 (Pubitemid 30086121)
34. Sakata T, Kario K, Matsuo T, Katayama Y, Matsuyama T, Kato H et al (1995) Suppression of plasma-activated factor VII levels by warfarin therapy. Arterioscler Thromb Vasc Biol 15(2):241-246
35. Weinstock DM, Chang P, Aronson DL, Kessler CM (1998) Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase. Am J Hematol 57:193-199 (Pubitemid 28139234)
36. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J (2005) Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous Thromboembolism. Br J Haematol 128:513-519 (Pubitemid 40283170)